Gilead's HIV franchise looks secure as 'son of Viread' impresses in PhIII

Two Phase III trials of Gilead Sciences' once-daily tablet containing its next-generation Viread product, tenofovir alafenamide (TAF), have met their primary objectives. The data are expected to help Gilead fight off generic competition to its hugely successful HIV franchise.